A structure-based designed small molecule depletes hRpn13Pru and a select group of KEN box proteins.

Autor: Lu, Xiuxiu, Chandravanshi, Monika, Sabbasani, Venkata R., Gaikwad, Snehal, Hughitt, V. Keith, Gyabaah-Kessie, Nana, Scroggins, Bradley T., Das, Sudipto, Myint, Wazo, Clapp, Michelle E., Schwieters, Charles D., Dyba, Marzena A., Bolhuis, Derek L., Koscielniak, Janusz W., Andresson, Thorkell, Emanuele, Michael J., Brown, Nicholas G., Matsuo, Hiroshi, Chari, Raj, Citrin, Deborah E.
Zdroj: Nature Communications; 3/20/2024, Vol. 15 Issue 1, p1-18, 18p
Abstrakt: Proteasome subunit hRpn13 is partially proteolyzed in certain cancer cell types to generate hRpn13Pru by degradation of its UCHL5/Uch37-binding DEUBAD domain and retention of an intact proteasome- and ubiquitin-binding Pru domain. By using structure-guided virtual screening, we identify an hRpn13 binder (XL44) and solve its structure ligated to hRpn13 Pru by integrated X-ray crystallography and NMR to reveal its targeting mechanism. Surprisingly, hRpn13Pru is depleted in myeloma cells following treatment with XL44. TMT-MS experiments reveal a select group of off-targets, including PCNA clamp-associated factor PCLAF and ribonucleoside-diphosphate reductase subunit M2 (RRM2), that are similarly depleted by XL44 treatment. XL44 induces hRpn13-dependent apoptosis and also restricts cell viability by a PCLAF-dependent mechanism. A KEN box, but not ubiquitination, is required for XL44-induced depletion of PCLAF. Here, we show that XL44 induces ubiquitin-dependent loss of hRpn13Pru and ubiquitin-independent loss of select KEN box containing proteins.Here, the authors identify a small molecule degrader (XL44) for hRpn13 and solve the XL44-hRpn13 structure. XL44 induces apoptosis in myeloma cells with hRpn13 dependency and also targets KEN box proteins PCLAF and RRM2. Loss of hRpn13 and PCLAF abrogates XL44 restriction of cell viability. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: